Liver Cancer

Hepatocellular carcinoma arises from liver cells. It is the disease most people mean by primary liver cancer. Cholangiocarcinoma, a cancer of the bile ducts, is a separate illness and is discussed with other hepato-pancreatico-biliary cancers. A mass in the liver on a scan may be hepatocellular carcinoma, a bile-duct cancer, a benign lesion, or a metastasis from somewhere else. Those are not interchangeable. The original site decides the medicines.

In a liver with cirrhosis, imaging patterns on a multiphase CT or MRI can be characteristic enough that a biopsy is not always required. When the diagnosis is uncertain, or when a biopsy would change the drug plan and can be done safely, tissue is taken. Bleeding risk and the amount of remaining liver function are part of that decision. A normal ultrasound last year does not cancel a new symptom or an abnormal blood test.

Chronic hepatitis B, chronic hepatitis C, cirrhosis from any cause, heavy alcohol use, and metabolic fat-related liver disease are the main risks. Aflatoxin exposure and some inherited liver diseases also contribute. Not everyone with hepatitis develops cancer, and treatment of viral hepatitis lowers later risk. People with cirrhosis are often offered ultrasound surveillance. Surveillance finds some cancers earlier. It does not guarantee that a cancer will be found in time, and it is not a substitute for treating the liver disease itself.

Family history of hepatitis matters because the virus can be shared. It is worth testing close contacts when hepatitis B is known. Vaccination prevents hepatitis B. It does not treat cancer that has already started. Alcohol and metabolic health remain relevant even after a diagnosis, because the liver that remains has to tolerate any treatment.

Early hepatocellular carcinoma often causes no symptom and is found on surveillance or on a scan done for another reason. Later symptoms can include pain or fullness in the upper abdomen, weight loss, a swollen abdomen from fluid, jaundice, itching, or a sudden worsening in someone who already has cirrhosis. Vomiting blood or black stools can come from pressure in the portal vein and is an emergency, whether or not cancer is the cause.

Tiredness and poor appetite are common in liver disease without cancer. They still deserve a review if they are new. A rising alpha-fetoprotein blood test can support suspicion in the right setting. AFP is not a screening test for the general public, and many liver cancers do not raise it. A normal AFP does not clear a mass.

Two things are staged at once: the cancer and the liver. Blood tests, bilirubin, clotting, albumin, and signs such as fluid or confusion describe how well the liver works. Child-Pugh and similar scores are clinical tools, not labels for a patient to memorise. A treatment that is reasonable in a working liver can be unsafe when jaundice or fluid is advanced. Viral hepatitis status is checked because it changes both the background disease and some drug risks.

CT or MRI with properly timed contrast shows the number and size of tumours and whether the portal vein is involved. A chest image looks for spread outside the liver. Knowing whether every lesion is in the liver, and whether the person could tolerate an operation or a local procedure, is what a liver surgeon or interventional specialist adds. Medical oncology is one part of that team, not a replacement for it.

Some small tumours are removed, or treated with ablation that destroys the spot without a large operation. Embolisation blocks the blood supply to the tumour and is done by an interventional radiologist. Transplant is considered in selected people with cirrhosis and a tumour within accepted limits. Those routes are led by liver teams. If they are possible, they are often better than starting a tablet and hoping. A medical oncologist helps decide when they are no longer the right next step.

Systemic therapy is used for many people with advanced disease, or when local treatment is not suitable. Targeted drugs and immunotherapy combinations are the medicines most often discussed. The choice depends on liver function, bleeding risk, prior treatment, and conditions such as autoimmune disease that can make immunotherapy unsafe. Not every person with a liver mass is fit for these drugs. Supportive care for appetite, pain, swelling, and confusion is part of the same plan. Outcomes vary widely and cannot be promised from a web page.

If the cancer in the liver came from the bowel or another organ, the treatment is the treatment of that original cancer. Giving a hepatocellular carcinoma drug in that situation is a mistake. This is why the biopsy and the scan history matter more than the phrase liver cancer used in conversation.

Targeted tablets can cause high blood pressure, hand-foot soreness, diarrhoea, and fatigue. Immunotherapy can inflame the liver, which is particularly important to notice in someone whose liver is already damaged. Fever, deepening jaundice, confusion, vomiting blood, or a rapidly swelling abdomen need urgent care. Pain medicines and sedatives that worsen confusion should be chosen carefully. Salt restriction and medicines for fluid are adjusted to the person. They are not optional extras.

Nutrition is difficult when appetite is poor. Small meals and treating nausea help some people. They do not replace cancer treatment and they do not reverse cirrhosis. Alcohol should be discussed openly. Continuing to drink against a scarred liver makes every later decision harder. Family members who are helping with medicines and clinic visits should hear the plan directly, including what would trigger an emergency visit.

Bring the multiphase CT or MRI report, AFP results, hepatitis tests, and a list of medicines for fluid, diabetes, or clotting. Mention alcohol use honestly and say whether you have already seen a liver surgeon or interventional radiologist. Prior ultrasound surveillance reports help show whether a nodule is new. If another cancer was treated in the past, bring that history, because a liver lesion may be a metastasis rather than a new primary.

Ask how well the liver is working, which treatments that function allows, and which it rules out. Ask whether a local procedure is still possible or whether systemic therapy is the realistic path. Ask how you will be monitored for confusion, bleeding, and blood pressure if a tablet or immunotherapy is started. Write down the warning signs that should not wait for the next appointment. The right plan is the one your liver can tolerate, not the one that sounds most aggressive.

A visit about liver cancer is used to read the records you already have, explain them in plain language, and outline options that may apply. Bring the biopsy or pathology report, scan CDs or reports, blood tests, and a list of treatment already given, including dates and drug names if you have them. A family member can come with you. The visit is not an emergency assessment, and it does not confirm a plan until the records have been reviewed.

Dr. Nishith Vaddeboina is a medical oncologist. Appointments published on this website are at American Oncology Institute, Nallagandla, Hyderabad. The biography also lists consultant work at Renova Century Hospitals. Confirm the hospital when you book. Plans are discussed against recognised guidance, including NCCN, ESMO, and ASCO, and then adjusted to the person in the room. Nothing on this page replaces that conversation.

Jaundice, a swollen abdomen, vomiting blood, black stools, or confusion need urgent assessment. A liver mass on a scan, or a surveillance ultrasound that is abnormal, needs a specialist review rather than a repeat test months later on your own. This page cannot tell a metastasis from a primary liver cancer.